New U.S. Biopharma Investment Watch: $425B+ Committed in 2025

America's biopharmaceutical sector is delivering unprecedented investment in domestic innovation and manufacturing capacity. In 2025 alone, life sciences companies have committed over $425 billion in new investments to bolster research and development, expand manufacturing, and create jobs across the country.

We Work For Health’s new tracking tool – the U.S. Biopharma Investment Watch – is documenting these developments and providing visibility into the sector's robust expansion and critical role in securing America's position as the global leader in healthcare innovation.

Key highlights from 2025 include:

• 1,273% increase in announced U.S. facility investments compared to 2024.

• Tens of thousands of new construction jobs to build and maintain these facilities.

• Faster delivery of breakthrough medicines to U.S. patients

These investments span the entire innovation ecosystem, from cutting-edge R&D facilities to advanced manufacturing plants that will bring breakthrough treatments closer to the patients who need them.

Today, America’s life sciences sector supports more than 4.9 million U.S. jobs and $71.6 billion in vendor spending. The positive impact of these investments reaches deep into U.S. communities, not only supporting roles for the scientists and engineers who will work in these new facilities, but also for the workers who will build, renovate and maintain them.

The biopharmaceutical industry’s investments reflect a commitment to ensuring the U.S. remains a global leader in the life sciences, but China continues a coordinated campaign to dominate the life sciences. Their efforts jeopardize America’s momentum, making it more important than ever to have smart policies in place that encourage continued investment and secure America’s future as the leading authority in this space.

You can access We Work For Health’s U.S. Biopharma Investment Watch to explore how these commitments are strengthening American innovation and competitiveness.